8-K filing — Karyopharm Therapeutics Inc. (KPTI)
Filed: 2026-08-13 AccNo: 0001193125-26-347897 Size: 535 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
Karyopharm Therapeutics (NASDAQ:KPTI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 12:54 PM
- Checked
- Aug 13, 2026, 12:54 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $133.736M Est
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $133.736 million estimate.
Read original at benzingaKaryopharm Therapeutics Q2 EPS $(2.32) Misses $(1.28) Estimate, Sales $33.432M Beat $32.188M Estimate
Read original at benzinga